Compound Genomic Alterations of TP53, PTEN, and RB1 Tumor Suppressors in Localized and Metastatic Prostate Cancer-Reference-Cited by-同舟云学术

Compound Genomic Alterations of TP53, PTEN, and RB1 Tumor Suppressors in Localized and Metastatic Prostate Cancer

Published:2019-07 Issue:1 Volume:76 Page:89-97
ISSN:0302-2838
Container-title:European Urology
language:en
Short-container-title:European Urology

Author:

Hamid Anis A.,Gray Kathryn P.,Shaw Grace,MacConaill Laura E.,Evan Carolyn,Bernard Brandon,Loda Massimo,Corcoran Niall M.,Van Allen Eliezer M.,Choudhury Atish D.,Sweeney Christopher J.

Publisher

Elsevier BV

Subject

Urology

Reference30 articles.

1. The molecular taxonomy of primary prostate cancer;Cancer Genome Atlas Research Network;Cell,2015

2. Integrative genomic profiling of human prostate cancer;Taylor;Cancer Cell,2010

3. Integrative clinical genomics of advanced prostate cancer;Robinson;Cell,2015

4. The long tail of oncogenic drivers in prostate cancer;Armenia;Nat Genet,2018

5. Genomic deletion of PTEN is associated with tumor progression and early PSA recurrence in ERG fusion-positive and fusion-negative prostate cancer;Krohn;Am J Pathol,2012

Cited by 176 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Characterizing the Tumor Microenvironment and Its Prognostic Impact in Breast Cancer;Cells;2024-09-10

2. MYBL2 Drives Prostate Cancer Plasticity: Inhibiting Its Transcriptional Target CDK2 for RB1-Deficient Neuroendocrine Prostate Cancer;Cancer Research Communications;2024-09-01

3. Metastatic hormone-naïve prostate cancer: a distinct biological entity;Trends in Cancer;2024-09

4. Evaluation of the prognostic role of TP53 gene mutations in prostate cancer outcome: A systematic review and meta-analysis;Clinical Genitourinary Cancer;2024-09

5. Development and Independent Validation of a Prognostic Gene Expression Signature Based on RB1, PTEN, and TP53 in Metastatic Hormone-sensitive Prostate Cancer Patients;European Urology Oncology;2024-08